Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours (Q33783119)

29 July 2017

Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours (English)

1 reference

ORCID Public Data File 2021

29 July 2017

1 reference

1 reference

1 reference

1 reference

author name string

N C Turner

1

1 reference

29 July 2017

S J Strauss

2

1 reference

29 July 2017

D Sarker

3

1 reference

29 July 2017

R Gillmore

4

1 reference

29 July 2017

A Kirkwood

5

1 reference

29 July 2017

A Hackshaw

6

1 reference

29 July 2017

A Papadopoulou

7

1 reference

29 July 2017

J Bell

8

1 reference

29 July 2017

I Kayani

9

1 reference

29 July 2017

C Toumpanakis

10

1 reference

29 July 2017

F Grillo

11

1 reference

29 July 2017

A Mayer

12

1 reference

29 July 2017

D Hochhauser

13

1 reference

29 July 2017

R H Begent

14

1 reference

29 July 2017

M E Caplin

15

1 reference

29 July 2017

T Meyer

16

1 reference

29 July 2017

language of work or name

English

0 references

publication date

16 March 2010

1 reference

British Journal of Cancer

29 July 2017

1 reference

29 July 2017

102

1 reference

29 July 2017

1106-1112

1 reference

29 July 2017

7

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6605618

29 July 2017

0 references

cites work

Alpha-fetoprotein and human chorionic gonadotrophin-beta as prognostic markers in neuroendocrine tumour patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2853102

One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2853102

Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2853102

Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2853102

Cytotoxic treatment including embolization/chemoembolization for neuroendocrine tumours

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2853102

TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2853102

Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2853102

A phase II trial of combination chemotherapy in patients with metastatic carcinoid tumors. A Southwest Oncology Group Study

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2853102

Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2853102

Treatment with cisplatin and etoposide in patients with neuroendocrine tumors

4 July 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605618

Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605618

A Phase II trial of gemcitabine for metastatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605618

Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605618

Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605618

Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605618

Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605618

Streptozocin Alone Compared with Streptozocin plus Fluorouracil in the Treatment of Advanced Islet-Cell Carcinoma

21 January 2018

1 reference

12 December 2020

Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor

1 reference

12 December 2020

Medical treatment and long-term survival in a prospective study of 84 patients with endocrine pancreatic tumors

1 reference

12 December 2020

Streptozocin–Doxorubicin, Streptozocin–Fluorouracil, or Chlorozotocin in the Treatment of Advanced Islet-Cell Carcinoma

1 reference

12 December 2020

Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma

1 reference

12 December 2020

A Phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors

1 reference

12 December 2020

Identifiers

DOI

10.1038/SJ.BJC.6605618

1 reference

Dimensions Publication ID

29 July 2017

0 references

1 reference

29 July 2017

1 reference